Immunobiology of gestational trophoblastic diseases

International Journal of Gynecological Cancer

Volumn 16, Issue 4, 2006, Pages 1500-1515

  Wang, X ^a,b   Fu, S ^a   Freedman, R S ^a   Liu, J ^a   Kavanagh, J J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Gestational trophoblastic disease; Immunology; Immunotherapy; Tumor

Indexed keywords

CA 125 ANTIGEN; CANCER VACCINE; CARBOXY TERMINAL PEPTIDE 37 DIPHTHERIA TOXOID VACCINE; CASPASE 8; CD45 ANTIGEN; CHEMOKINE; CHORIONIC GONADOTROPIN; COMPLEMENT; CYTOKINE; DENDRITIC CELL VACCINE; DNA VACCINE; FAS ANTIGEN; FAS LIGAND; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELANOMA ANTIGEN 1; NY ESO 1 ANTIGEN; PLACENTA LACTOGEN; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER INFILTRATION; CANCER MODEL; CELL POPULATION; CHORIOCARCINOMA; COMPLEMENT ACTIVATION; CYTOKINE RELEASE; DECIDUA; DISEASE MARKER; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMORAL IMMUNITY; IMMUNOBIOLOGY; IMMUNOGENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; IMMUNOSURVEILLANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; MYOMETRIUM; NATURAL KILLER T CELL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYNCYTIOTROPHOBLAST; T LYMPHOCYTE ACTIVATION; TROPHOBLAST; TROPHOBLASTIC TUMOR; VIRUS CARCINOGENESIS; VIRUS ETIOLOGY;

ANTIGENS, NEOPLASM; FEMALE; GESTATIONAL TROPHOBLASTIC NEOPLASMS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; LYMPHOKINES; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC;

EID: 33745958844     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00539.x     Document Type: Review

References (137)

1. Scully RE, Bonfiglio TA, Kurman RJ et al. Histological typing of female genital tract tumors. Vol. 2nd edn. New York, NY: Springer Verlag, 1994.
2. Kohorn EI. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment. Int J Gynecol Cancer 2001;11:73-7.
3. Ngan HY, Bender H, Benedet JL et al. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2003;83(Suppl. 1):175-7.
4. Wright JD, Mutch DG. Treatment of high-risk gestational trophoblastic tumors. Clin Obstet Gynecol 2003;46:593-606.
5. Lurain JR. Management of high-risk gestational trophoblastic disease. J Reprod Med 1998;43:44-52.
6. Berkowitz RS, Goldstein DP, Anderson DJ. Recent advances in understanding the immunobiology of gestational trophoblastic disease - a review. Trophoblast Res 1987;2:123.
7. Bianchi DW, Zickwolf GK, Weil GJ et al. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc Natl Acad Sci U S A 1996;93:705-8.
8. Steler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993;9:541-73.
9. Okamoto T, Niu R, Yamada S et al. Reduced expression of tissue inhibitor of metalloproteinase (TIMP)-2 in gestational trophoblastic diseases. Mol Hum Reprod 2002;8:392-8.
10. Choudhury SR, Knapp LA. Human reproductive failure II: immunogenetic and interacting factors. Hum Reprod Update 2001;7:135-60.
11. Szekeres-Bartho J. Immunological relationship between the mother and the fetus. Int Rev Immunol 2002;21:471-95.
12. Harris JR. Placental endogenous retrovirus (ERV): structural, functional, and evolutionary significance. Bioessays 1998;20:307-16.
13. Boyson JE, Rybalov B, Koopman LA et al. CD1d and invariant NKT cells at the human maternal-fetal interface. Proc Natl Acad Sci U S A 2002;99:13741-6.
14. Tuo W, Bazer FW. Expression of oncofetal fibronectin in porcine conceptuses and uterus throughout gestation. Reprod Fertil Dev 1996;8:1207-13.
15. Nagata S, Goldstein P. The Fas death factor. Science 1995;267:1449-56.
16. Baban B, Chandler P, McCool D et al. Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol 2004;61:67-77.
17. Guller S, LaChapelle L. The role of placental Fas ligand in maintaining immune privilege at maternal-fetal interfaces. Semin Reprod Endocrinol 1999;17:39-44.
18. Morgan BP, Holmes CH. Immunology of reproduction: protecting the placenta. Curr Biol 2000;10:381-3.
19. Lower R, Lower J, Kurth R. The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Proc Natl Acad Sci U S A 1996;93:5177-84.
20. Mwenda JM, Mahler PM, Melling GC et al. A murine monoclonal antibody (RV3-27) raised against isolated human placental endogenous retroviral particles and reactive with syncytiotrophoblast. J Reprod Immunol 1994;26:75-95.
21. Johnson PM, Lyden TW, Mwenda JM. Endogenous retroviral expression in the human placenta. Am J Reprod Immunol 1990;23:115-20.
22. Astrid H, Dohr G. Expression of Fas-ligand in first trimester and term human placental villi. J Reprod Immunol 2000;46:83-90.
23. Kauma SW, Huff TF, Hayes N et al. Placental Fas ligand expression is a mechanism for maternal immune tolerance to the fetus. J Clin Endocrinol Metab 1999;84:2188-94.
24. Sapi E, Brown WD, Aschkenazi S et al. Regulation of Fas ligand expression by estrogen in normal ovary. J Soc Gynecol Investig 2002;9:243-50.
25. Aschkenazi S, Straszewski S, Verwer KMA et al. Differential regulation and function of the Fas/Fas ligand system in human trophoblast cells. Biol Reprod 2002;66:1853-61.
26. Holmes CH, Simpson KL. Complement and pregnancy: new insights into the immunobiology of the fetomaternal relationship. Baillieres Clin Obstet Gynaecol 1992;6:439-60.
27. Holmes CH, Simpson KL, Okada H et al. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55). Eur J Immunol 1992;22:1579-85.
28. Holmes CH, Simpson KL, Wainwright SD et al. Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy. J Immunol 1990;144:3099-105.
29. Xu C, Mao D, Holers VM et al. A critical role for murine complement regulator crry in fetomaternal tolerance. Science 2000;287:498-501.
30. Santoso DIS, Rogers P, Wallace EM et al. Localization of indoleamine 2,3-dioxygenase and 4-hydroxynonenal in normal and pre-eclamptic placentae. Placenta 2002;23:373-79.
31. Frumento G, Rotondo R, Tonetti M et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002;196:459-68.
32. Mellor AL, Sivakumar J, Chandler P et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2001;2:64-8.
33. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-45.
34. Sato Y, Higuchi T, Yoshioka S et al. Trophoblasts acquire a chemokine receptor, CCR1, as they differentiate towards invasive phenotype. Development 2003;130:5519-32.
35. Bowen JM, Chamley L, Mitchell MD et al. Cytokines of the placenta and extra-placental membranes: biosynthesis, secretion and roles in establishment of pregnancy in women. Placenta 2002;23:239-56.
36. Bazer FW, Spencer TE, Ott TL. Placental interferons. Am J Reprod Immunol 1996;35:297-308.
37. Deniz G, Christmas SE, Johnson PM. Soluble mediators and cytokines produced by human CD3-leucocyte clones from decidualized endometrium. Immunology 1996;87:92-8.
38. Piccinni MP, Beloni L, Livi C et al. Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions. Nat Med 1998;4:1020-4.
39. Ain R, Canham LN, Soares MJ. Gestation stage-dependent intra-uterine trophoblast cell invasion in the rat and mouse: novel endocrine phenotype and regulation. Dev Biol 2003;260:176-90.
40. Bauer S, Pollheimer J, Hartmann J et al. Tumor necrosis factor-alpha inhibits trophoblast migration through elevation of plasminogen activator inhibitor-1 in first-trimester villous explant cultures. J Clin Endocrinol Metab 2004;89:812-22.
41. Karmakar S, Das C. Regulation of trophoblast invasion by IL-1beta and TGF-beta1. Am J Reprod Immunol 2002;48:210-9.
42. Chakraborty C, Gleeson LM, McKinnon T et al. Regulation of human trophoblast migration and invasiveness. Can J Physiol Pharmacol 2002;80:116-24.
43. Mapara MY, Sylvester S. Tolerance and cancer: mechanism of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004;22:1136-51.
44. Zou W. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-74.
45. Hansen HE, Vejerslev LO, Olesen LS et al. HLA and hydatidiform mole. I. HLA and ABO antigen frequencies in couples with androgenetic and diandric conceptuses. Tissue Antigens 1988;32:87-92.
46. Souka AR, Kholeif A, Zaki S et al. Human leukocyte antigen in hydatidiform mole. Int J Gynaecol Obstet 1993;41:257-60.
47. Sbracia M, Scarpellini F, Mastrone M et al. HLA antigen sharing in Italian couples in which women were affected by gestational trophoblastic tumors. Am J Reprod Immunol 1996;35:252-5.
48. Goldman-Wohl D, Ariel I, Greenfield C et al. A study of human leukocyte antigen G expression in hydatidiform moles. Am J Obstet Gynecol 2001;185:476-80.
49. Rabreau M, Rouas-Freiss N, Landi M et al. HLA-G expression in trophoblast cells is independent of embryonic development. Hum Immunol 2000;61:1108-12.
50. Singer G, Kurman RJ, McMaster MT et al. HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am J Surg Pathol 2002;26:914-20.
51. Le Bouteiller P. HLA class I chromosomal region, genes, and products: facts and questions. Crit Rev Immunol 1994;14:89.
52. Ellis SA, Strachan T, Palmer MS et al. Complete nucleotide sequence of a unique HLA class I C locus product expressed on the human choriocarcinoma cell line BeWo. J Immunol 1989;142:3281-5.
53. Koc S, Kather A, Markert UR et al. Enhancement of immunogenicity of Jeg3 cells by ectopic expression of HLA-A*0201 and CD80. Am J Reprod Immunol 2003;50:243-53.
54. Krishnan L, Sad S, Raghupathy R. Characterization of an immunosuppressive factor secreted by a human trophoblast-derived choriocarcinoma cell line. Cell Immunol 1995;162:295-308.
55. Wolf RL, Ilekis J, Benveniste R. Characterization of an immune suppressor from transformed human trophoblastic Jeg-3 cells. Cell Immunol 1983;78:356-67.
56. Markert UR, Chaouat G. Preliminary characterization of an immunosuppressive inducer factor secreted by the JEG-3 choriocarcinoma cell line: in vitro and in vivo studies. Am J Reprod Immunol 1997;38:327-38.
57. Markert UR, Chaouat G. Biological activity of the suppressor cells inducer factor secreted by the Jeg-3 choriocarcinoma cell line. Am J Reprod Immunol 2001;46:332-41.
58. Markert UR, Kilic M, Schleussner E et al. Choriocarcinoma-induced suppression of lymphocyte activity. J Investig Allergol Clin Immunol 2000;10:323-6.
59. Moffett-King A. Natural killer cells and pregnancy. Nat Immunol 2002;2:656-63.
60. Trundley A, Moffett A. Human uterine leukocytes and pregnancy. Tissue Antigens 2004;63:1-12.
61. Heikkinen J, Mottonen M, Komi J et al. Phenotypic characterization of human decidual macrophages. Clin Exp Immunol 2003;131:498-505.
62. Mor G, Abrahams V. Potential role of macrophages as immunoregulators of pregnancy. Reprod Biol Endocrinol 2003;1:119-6.
63. Bartho JS, Barakonyi A, Miko E et al. The role of alpha/delta T cells in the feto-maternal relationship. Semin Immunol 2001;13:229-33.
64. Kabawat SE, Mostoufi-Zadeh M, Berkowitz RS et al. Implantation site in complete molar pregnancy: a study of immunologically competent cells with monoclonal antibodies. Am J Obstet Gynecol 1985;152:97-9.
65. Wongweragiat S, Searle RF, Bulmer JN. Decidual T lymphocyte activation in hydatidiform mole. J Clin Pathol 1999;52:888-94.
66. Knoeller S, Lim E, Aleta L et al. Distribution of immunocompetent cells in decidua of controlled and uncontrolled (choriocarcinoma/hydatidiform mole) trophoblast invasion. Am J Reprod Immunol 2003;50:41-7.
67. Pongcharoen S, Searle RF, Bulmer JN. Placental fas and fas ligand expression in normal early, term and molar pregnancy. Placenta 2004;25:321-30.
68. Hammer A, Hartmann M, Sedlmayr P et al. Expression of functional Fas ligand in choriocarcinoma. Am J Reprod Immunol 2002;48:226-34.
69. Wongweragiat S, Searle RF, Bulmer JN. Expression of Fas/Fas ligand by decidual leukocytes in hydatidiform mole. Biol Reprod 2001;64:784-9.
70. Rajashekhar G, Loganath A, Roy AC et al. Resistance to Fas-mediated cell death in BeWo and NJG choriocarcinoma cell lines: implications in immune privilege. Gynecol Oncol 2003;91:89-100.
71. Krueger A, Baumann S, Krammer PH et al. FLICE-inhibitory proteins: regulation of death receptor-mediated apoptosis. Mol Cell Biol 2001;21:8147-54.
72. Rango UV, Classen-Linke I, Raven G et al. Cytokine microenvironments in human first trimester decidua are dependent on trophoblast cells. Fertil Steril 2003;79:1176-86.
73. Rieger L, Kammerer U, Hofmann J et al. Choriocarcinoma cells modulate the cytokine production of decidual large granular lymphocytes in coculture. Am J Reprod Immunol 2001;46:137-43.
74. Raghupathy R, Makhseed M, Azizieh F et al. Maternal Th1- and Th2-type reactivity to placental antigens in normal human pregnancy and unexplained recurrent spontaneous abortions. Cell Immunol 1999;196:122-30.
75. Shaarawy M, Darwish NA. Serum cytokines in gestational trophoblastic diseases. Acta Oncol 1995;34:177-82.
76. Kato HD, Terao Y, Ogawa M et al. Growth-associated gene expression profiles by microarray analysis of trophoblast of molar pregnancies and normal villi. Int J Gynecol Pathol 2002;21:255-60.
77. Pawelec G. Tumor escape: antitumour effectors too much of a good thing?. Cancer Immunol Immunother 2004;53:262-74.
78. Pang ZJ, Xing FQ. Expression of transforming growth factor-beta and insulin-like growth factor in molar and placental tissues. Arch Gynecol Obstet 2003;269:1-4.
79. Simpson H, Robson SC, Bulmer JN et al. Transforming growth factor beta expression in human placenta and placental bed during early pregnancy. Placenta 2002;23:44-58.
80. Graham CH, Connelly I, MacDougall JR et al. Resistance of malignant trophoblast cells to both the anti-proliferative and anti-invasive effects of transforming growth factor-beta. Exp Cell Res 1994;214:93-9.
81. Filmus J, Kerbel R. Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor-beta during tumor progression. Curr Opin Oncol 1990;5:123-9.
82. Xu G, Chakraborty C, Lala PK. Expression of TGF-beta signaling genes in the normal, premalignant, and malignant human trophoblast: loss of smad3 in choriocarcinoma cells. Biochem Biophys Res Commun 2001;287:47-55.
83. Xu G, Chakraborty C, Lala PK. Restoration of TGF-beta regulation of plasminogen activator inhibitor-1 in Smad3-restituted human choriocarcinoma cells. Biochem Biophys Res Commun 2002;294:1079-86.
84. Xu G, Chakraborty C, Lala PK. Reconstitution of Smad3 restores TGF-beta response of tissue inhibitor of metalloprotease-1 upregulation in human choriocarcinoma cells. Biochem Biophys Res Commun 2003;300:383-90.
85. Roth I, Corry DB, Locksley RM et al. Human placental cytotrophoblasts produce the immunosuppressive cytokine interleukin 10. J Exp Med 1996;184:539-48.
86. Bennett WA, Lagoo-Deenadayalan S, Whitworth NS et al. Expression and production of interleukin-10 by human trophoblast: relationship to pregnancy immunotolerance. Early Pregnancy 1997;3:190-8.
87. Salgado R, Junius S, Benoy I et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003;103:642-6.
88. Frassanito MA, Cusmai A, Iodice G et al. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001;97:483-9.
89. Bennett WA, Lagoo-Deenadayalan S, Brackin MN et al. Cytokine expression by models of human trophoblast as assessed by a semi-quantitative reverse transcription-polymerase chain reaction technique. Am J Reprod Immunol 1996;36:285-94.
90. Fujisawa K, Nasu K, Arima K et al. Production of interleukin (IL)-6 and IL-8 by a choriocarcinoma cell line, BeWo. Placenta 2000;21:354-60.
91. Drews K, Nowak-Markwitz E, Brzezinska E et al. Analysis of interleukin-6 serum concentration in trophoblastic tumors prognosis. Ginekol Pol 2000;71:758-63.
92. Mapara MY, Sylvester S. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004;22:1136-51.
93. Shaarawy M, el-Shobokshy AS, el-Noury AI. Serum granulocyte macrophage colony stimulating factor (GM-CSF) in gestational trophoblastic diseases. Cytokine 1995;7:171-5.
94. Rovelli F, Lissoni P, Crispino S et al. Increased level of soluble interleukin-2 receptor in advanced solid tumors: a preliminary study. Tumori 1988;74:633-7.
95. Shaarawy M, Darwish NA, Abdel-Aziz O. Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases. J Soc Gynecol Investig 1996;3:39-46.
96. Kayisli UA, Selam B, Guzeloglu-Kayisli O et al. Human chorionic gonadotropin contributes to maternal immunotolerance and endometrial apoptosis by regulating Fas-Fas ligand system. J Immunol 2003;171:2305-13.
97. Perkins GL, Slater ED, Sanders GK et al. Serum tumor markers. Am Fam Physician 2003;68:1075-82.
98. Lin J, Lei ZM, Lojun S et al. Increased expression of luteinizing hormone/human chorionic gonadotropin receptor gene in human endometrial carcinomas. J Clin Endocrinol Metab 1994;79:1483-91.
99. Triozzi PL, Stevens V. Human chorionic gonadotropin as a target for cancer vaccines. Oncol Rep 1999;6:7-17.
100. Hearn JP, Gidley-Baird AA, Hodges JK et al. Embryonic signals during the peri-implantation period in primates. J Reprod Fertil Suppl 1988;36:49-58.
101. Talwar GP, Singh O, Pal R et al. A vaccine that prevents pregnancy in women. Proc Natl Acad Sci U S A 1994;91:8532-6.
102. Gillott DJ, Iles RK, Chard T. The effects of beta-human chorionic gonadotrophin on the in vitro growth of bladder cancer cell lines. Br J Cancer 1996;73:323-6.
103. Neulen J, Raczek S, Pogorzelski M et al. Secretion of vascular endothelial growth factor/vascular permeability factor from human luteinized granulosa cells is human chorionic gonadotrophin dependent. Mol Hum Reprod 1998;4:203-6.
104. Moulton HM, Yoshihara PH, Mason DH et al. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin Cancer Res 2002;8:2044-51.
105. Terrazzini N, Hannesdottir S, Delves PJ et al. DNA immunization with plasmids expressing hCGbeta-chimeras. Vaccine 2004;22:2146-53.
106. Dangles V, Halberstam I, Scardino A et al. Tumor-associated antigen human chorionic gonadotropin beta contains numerous antigenic determinants recognized by in vitro-induced CD8+ and CD4+ T lymphocytes. Cancer Immunol Immunother 2002;50:673-81.
107. He LZ, Ramakrishna V, Connolly JE et al. A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin beta. Clin Cancer Res 2004;10:1920-7.
108. Knecht M. Effect of hCGbeta-tt immunization on ovarian morphology in hamster implanted with human choriocarcinoma. Contraception 1980;21:425-32.
109. Knecht M. The lack of an effect of active immunization with the beta-subunit of chorionic gonadotropin coupled to tetanus toxoid on the growth of human choriocarcinoma maintained in the hamster cheek pouch. Endocrinology 1980;106:150-4.
110. Cinader B, Hayley MA, Rider WD et al. Immunotherapy of a patient with choriocarcinoma. Can Med Assoc J 1961;84:306-9.
111. Jakoubkova J, Koldovsky P, Bek V et al. To the problem of immunotherapy of choriocarcinoma. Neoplasma 1965;12:531-42.
112. Robinson E, Ratzkowski E. Chemotherapy and immunotherapy of a patient with choriocarcinoma. Gynaecologia 1965;160:87-93.
113. Bagshawe KD. Immunotherapy of human cancer - its prospects. Choriocarcinoma. Proc R Soc Med 1971;64:1043-4.
114. Bagshawe KD. Immunity and immunotherapy in patients with trophoblastic choriocarcinoma. Schweiz Med Wochenschr 1972;102:1161-3.
115. Nisula BC, Kohler PO. Effect of antiserum to human chorionic gonadotropin on growth and function of choriocarcinoma in vivo and in vitro. Cancer Res 1974;34:512-5.
116. Ohkawa R, Ohkawa K, Tosaka N et al. Complement system in abnormal pregnancy and chorionic neoplasia: immunotherapy and chemotherapy of chorionic neoplasia. Adv Exp Med Biol 1984;176:111-25.
117. Olovsson M, Larsson E, Nilsson BO. Immunizing with mouse trophoblast to obtain mouse-human cross-reacting antibodies against normal and neoplastic human trophoblast. Hybridoma 1999;18:529-34.
118. Morrish DW, Dakour J, Li H. Functional regulation of human trophoblast differentiation. J Reprod Immunol 1998;39:179-95.
119. Han VK, Bassett N, Walton J et al. The expression of insulin-like growth factor (IGF) and IGF-binding protein (IGFBP) genes in the human placenta and membranes: evidence for IGF-IGFBP interactions at the feto-maternal interface. J Clin Endocrinol Metab 1996;81:2680-93.
120. Cervar M, Huppertz B, Barth S et al. Endothelin A and B receptors change their expression levels during development of human placental villi. Placenta 2000;21:536-46.
121. Hamilton GS, Lysiak JJ, Han VKM et al. Autocrine-paracrine regulation of human trophoblast invasiveness by insulin-like growth factor (IGF)-II and IGF-binding protein (IGFBP)-1*1. Exp Cell Res 1998;244:147-56.
122. Mohan A, Asselin J, Sargent IL et al. Effect of cytokines and growth factors on the secretion of inhibin A, activin A and follistatin by term placental villous trophoblasts in culture. Eur J Endocrinol 2001;145:505-11.
123. Caniggia I, Lye SJ, Cross JC. Activin is a local regulator of human cytotrophoblast cell differentiation. Endocrinology 1997;138:3976-86.
124. Leach RE, Kilburn B, Wang J et al. Heparin-binding EGF-like growth factor regulates human extravillous cytotrophoblast development during conversion to the invasive phenotype. Dev Biol 2004;266:223-37.
125. Isaka K, Usuda S, Ito H et al. Expression and activity of matrix metalloproteinase 2 and 9 in human trophoblasts. Placenta 2003;24:53-64.
126. Floridon C, Nielsen O, Holund B et al. Localization and significance of urokinase plasminogen activator and its receptor in placental tissue from intrauterine, ectopic and molar pregnancies. Placenta 1999;20:711-21.
127. Xu G, Guimond MJ, Chakraborty C et al. Control of proliferation, migration, and invasiveness of human extravillous trophoblast by decorin, a decidual product. Biol Reprod 2002;67:681-9.
128. Shih IM, Kurman RJ. Expression of melanoma cell adhesion molecule in intermediate trophoblast. Lab Invest 1996;75:377-88.
129. Caniggia I, Winter JL. Adriana and Luisa Castellucci Award lecture 2001. Hypoxia inducible factor-1: oxygen regulation of trophoblast differentiation in normal and pre-eclamptic pregnancies - a review. Placenta 2002;23(Suppl. A):S47-57.
130. Floridon C, Nielsen O, Holund B et al. Does plasminogen activator inhibitor-1 (PAI-1) control trophoblast invasion? A study of fetal and maternal tissue in intrauterine, tubal and molar pregnancies. Placenta 2000;21:754-62.
131. Liu Z, Chen Y, Yang Y et al. The effect on MHC class II expression and apoptosis in placenta by IFN gamma administration. Contraception 2002;65:177-84.
132. Yui J, Garcia-Lloret M, Wegmann TG et al. Cytotoxicity of tumour necrosis factor-alpha and gamma-interferon against primary human placental trophoblast. Placenta 1994;15:819-35.
133. Ponte M, Cantoni C, Biassoni R et al. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc Natl Acad Sci U S A 1999;96:5674-9.
134. Morales PJ, Pace JL, Platt JS et al. Placental cell expression of HLA-G2 isoforms is limited to the invasive trophoblast phenotype. J Immunol 2003;171:6215-24.
135. King A, Allan DS, Bowen M et al. HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells. Eur J Immunol 2000;30:1623-31.
136. Ishitani A, Sageshima N, Lee N et al. Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. J Immunol 2003;171:1376-84.
137. King A, Burrows TD, Hiby SE et al. Surface expression of HLA-C antigen by human extravillous trophoblast. Placenta 2000;21:376-87.